Wednesday, July 11, 2018

Cingulate raises $7.5m for controlled-release ADHD therapy - Mass Device


Mass Device

Cingulate raises $7.5m for controlled-release ADHD therapy
Mass Device
The Kansas City-based company is working on a set of therapies that utilize its 'Precision Time Release' drug-delivery platform. Cingulate's CEO, Shane Schaffer, told Drug Delivery Business News that his company set out to create an ADHD therapy that ...
KCK pharma startup lands $7.5M, new board memberKansas City Business Journal
Cingulate Therapeutics Announces $7.5M Equity Investment from Werth Family Investment AssociatesPR Newswire (press release)

all 2 news articles »

No comments:

Post a Comment